FDA-posted recall of ReBoost nasal spray
MediNatura New Mexico, Inc. voluntarily recalled one lot of ReBoost Nasal Spray nationwide after tests found yeast/mold and Achromobacter contamination above specifications, according to an FDA-posted notice this week. The affected 20 mL bottles (NDC 62795-4005-9; UPC 787647101863; Lot 224268, exp 12/2027) were sold online and at retailers nationwide; users—especially those who are immunocompromised—are urged to stop using the product and seek refunds/returns and to report adverse events to FDA MedWatch.
📌 Key Facts
- One lot recalled: Lot 224268, expiration 12/2027 (20 mL bottle in white/yellow carton)
- Product IDs: NDC 62795-4005-9; UPC 787647101863; distributed nationwide via retail and internet
- Contamination: yeast/mold and Achromobacter; no adverse events reported to date
- Consumer guidance: discontinue use; contact recall@medinatura.com for refunds if bought direct or return to retailer; report issues to FDA MedWatch
📊 Relevant Data
In 2022, 242 million phenylephrine products were sold in the US, generating $1.76 billion in sales.
The prevalence of immunosuppression among US adults in 2021 was 6.6%, with rates varying by race/ethnicity: 8.4% for American Indian or Alaska Native, 7.4% for non-Hispanic White, 6.1% for non-Hispanic Black, 5.0% for Hispanic, and 3.7% for non-Hispanic Asian.
Homeopathic products have not been approved by FDA for any use and may not meet modern standards for safety, effectiveness, and quality.
Homeopathic Products — FDA